Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance

ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.

HLAL trades at $72.93, showing minimal daily movement with a slight 0.06% decline. Technical indicators present a mixed picture with bullish moving averages but neutral oscillators, while the stock lacks comprehensive fundamental data for traditional valuation metrics. The upcoming dividend of $0.02 per share scheduled for June 2026 provides a modest income component.

The stock's outlook remains uncertain due to limited financial disclosures. Investment opportunity hinges on future earnings visibility and market positioning, while primary risks include information gaps and market volatility. Further fundamental analysis requires updated SEC filings and earnings reports to assess true valuation potential.